Stamulumab

Tax included
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.
MedChemExpress 
HY-P99588

Data sheet

Size
Multiple sizes
Reactivity
TGF-β Receptor
Application
Metabolism-protein/nucleotide metabolism
CAS
705287-60-1